JBT is developing a therapy for ischemic heart disease involving the regeneration of cardiac muscle by inhibiting miRs suppressed in the evolution process.
Only investors on Gust who have been granted access can view this content.
Interested in this startup? Sign In or Sign Up to request more information.
Starting a startup?
Join the world's largest startup network for guidance, tools, and fundraising opportunities.
Get Started for Free